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Abstract
Early lung inflammation has been implicated in the pathogenesis of bronchopulmonary dysplasia (BPD). We aimed to establish
the efficacy and safety of systemic hydrocortisone for the prevention of BPD. A systematic review and meta-analysis were
undertaken, with a detailed electronic literature search. Trials involving preterm infants were included if they were randomised to
receive systemic hydrocortisone or a placebo. The primary outcome was the composite of survival without BPD at 36-week
postmenstrual age (PMA). Results are presented as relative risk (RR) or risk difference (RD) with 95% confidence intervals (CIs),
along with numbers needed to treat (NNT) or harm (NNH). After filtering, 12 studies using early (within 1 week of birth) and two
using late hydrocortisone were identified. Early systemic hydrocortisone significantly increased the chances of survival without
BPD (RR 1.13, 95% CI [1.01, 1.26], NNT 18), and survival without moderate-to-severe neurodevelopmental impairment (1.13
[1.02, 1.26], NNT 14). Infants who received hydrocortisone had a higher risk of intestinal perforation (1.69 [1.07, 2.68], NNH
30), primarily with concurrent treatment for patent ductus arteriosus.
Conclusion: Early systemic hydrocortisone is a modestly effective therapy for the prevention of BPD in preterm infants,
although some safety concerns remain. No conclusions could be drawn for late hydrocortisone due to the paucity of studies.
What is Known:
• Preterm infants are at high risk of developing bronchopulmonary dysplasia (BPD) and early lung inflammation plays a significant role in its
pathogenesis.
• Both early and late systemic dexamethasone seems to reduce the incidence of BPD, but its use is associated with serious neurodevelopmental
impairment at follow-up.
What is New:
• Early systemic hydrocortisone significantly improved survival without BPD at 36 weeks and survival without moderate to severe neurodevelopmental
impairment on follow up.
• Incidence of gastrointestinal perforation associated with concurrent treatment for PDA was significantly higher, although early systemic
hydrocortisone reduced the need for treatment of PDAs.
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Abbreviations
BPD Bronchopulmonary dysplasia
CENTRAL Cochrane Central Register of Controlled Trials
CI Confidence intervals
CP Cerebral palsy
GA Gestational age
GI Gastrointestinal
IVH Intraventricular haemorrhage
MD Mean differences
MeSH Medical Subject Headings
NDI Neurodevelopmental impairment
NEC Necrotising enterocolitis
NNH Number needed to harm
NNT Number needed to treat
PDA Patent ductus arteriosus
PMA Postmenstrual age
PVL Periventricular leucomalacia
RCT Randomised controlled trial
ROP Retinopathy of prematurity
RR Risk ratio
SD Standard deviation
Introduction
Bronchopulmonary dysplasia (BPD) remains a common com-
plication of preterm birth [1] and is associated with long-term
pulmonary morbidity [2, 3] and neurodevelopmental impair-
ment (NDI) [4]. Whilst BPD is multi-factorial in aetiology,
persistent pulmonary inflammation beginning in utero and
continued postnatally by factors including mechanical venti-
lation, oxidative stress and sepsis has been strongly implicated
in the development of the disease [5]. Consequently, cortico-
steroids as potent anti-inflammatory agents could be of use in
reducing the risk of developing BPD.
To date, most studies have considered systemic dexa-
methasone as the drug of choice in preventing or treating
BPD [6, 7]. Benefits appear to include reduction in the
need for mechanical ventilation, the incidence of BPD at
28 days and 36 weeks postmenstrual age (PMA), and
neonatal mortality [6, 7]. However, concerns over long-
term neurodevelopmental outcome, particularly when
used within the first 7 days of life [6], have led to a more
cautious approach in recent years [8] with dexamethasone
use usually being reserved for those infants who are ven-
tilator dependant beyond the first few weeks of life.
Systemic hydrocortisone has been postulated as a potentially
safer drug to use in terms of long-term neurodevelopment [9,
10]. Several cohort studies have suggested no adverse effect on
brain volume or neurodevelopmental outcome in infants receiv-
ing systemic hydrocortisone [9, 11], but prospective evidence
supporting any benefit in facilitating extubation or reducing
rates of BPD have been limited [12]. The Cochrane Neonatal
Group recently updated a meta-analysis of efficacy and safety
of systemic steroids in preterm infants, which included data on
both hydrocortisone and dexamethasone. We conducted a spe-
cific and detailed systematic review and meta-analysis of sys-
temic hydrocortisone to assess the efficacy of early (within the
first week of life) or late (beyond the first week of life) postnatal
use for the prevention of BPD in preterm infants compared to
placebo or active control, along with its short- and long-term
safety. Our analysis includes data from two extra studies, one
using early hydrocortisone and a recent large study using late
hydrocortisone. We have compared more clinically relevant
outcomes (treated for hypertension, hyperglycaemia, patent
ductus arteriosus [PDA] or retinopathy of prematurity [ROP],
rather than incidence) to help clinicians in taking decisions on
the ward. In addition, we have conducted a sub-group analysis
of studies which had short-term respiratory endpoints as their
primary outcome (BPD studies), excluding studies where hy-
drocortisone was used to treat hypotension, for more robust
results.
Methods
Objectives
A systematic review and meta-analysis, using methods from
the Cochrane Collaboration, to assess the efficacy and safety
of systemic hydrocortisone for the prevention of BPD in pre-
term infants (< 37 weeks gestational age [GA] at birth), when
compared with placebo (or other non-steroidal active control
with no known effect on BPD) in published studies.
Inclusion criteria
Prospective RCTs involving preterm infants were eligible for
inclusion in the review. Trials were included if participating
infants were randomised to receive systemic hydrocortisone
(with or without a second active drug which has no known
effects on BPD) started within the first week after birth (early)
or after the first week (late), or a placebo (or any other non-
steroidal active control with no known effects on BPD), and
reported outcomes relevant to the review (please see below).
Studies were grouped according to whether hydrocortisone
was started early, or late, and separate analyses were conduct-
ed for each group.
Search strategy
We developed a search strategy using keywords and MESH
terms, as detailed in the supplementary information, from two
main databases: Embase andMedline. A separate search using
keyword was conducted on the Cochrane Central Register of
Controlled Trials (CENTRAL). The databases were searched
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in March 2018, at the end of the third week. This search was
rerun in February 2019, and one further relevant paper on late
hydrocortisone was identified. References in included studies
were also screened manually for inclusion. The search includ-
ed papers in all languages from all countries.
Outcomes
The primary outcome was survival without BPD at 36 weeks
PMA (composite outcome). Data on several secondary out-
comes were collected, including those on efficacy (survival to
36 weeks PMA and to discharge, and BPD at 36 weeks in
survivors), short-term safety (sepsis, pulmonary air-leak or
haemorrhage, gastrointestinal [GI] bleeding or perforation,
hyperglycaemia and its treatment, hypertension and its treat-
ment, intraventricular haemorrhage [IVH], periventricular
leucomalacia [PVL] and necrotising enterocolitis [NEC]), oth-
er relevant short-term outcomes (home oxygen in survivors,
duration of mechanical ventilation and total stay, patent ductus
arteriosus [PDA] and its treatment, and retinopathy of prema-
turity [ROP] and its treatment) and long-term safety outcomes
up to 2 years of age (death until last follow-up, survival with-
out any NDI, survival without moderate-to-severe NDI, any
and severe NDI at follow up and cerebral palsy [CP]).
Definitions
BPD was defined as respiratory support and/or supplemental
oxygen requirement at 36 weeks corrected GA and classified
as moderate or severe BPD by Jobe and Bancalari. [13]
Grades of IVH were as classified by Lu-Ann Papile [14].
Modified classification of NEC was by Walsh et al. [15].
PVL, PDA, ROP andNDIwere defined as reported by authors
in the studies.
Data collection
Data was collected on characteristics of studies and planned
outcomes using a standardised data collection form
(supplementary Table 1) by at least two authors independently
and then cross-checked for accuracy. Attempts were made to
clarify methods and request additional data from correspond-
ing authors if data on some relevant outcomes were not re-
ported. These are mentioned in the relevant tables in the
BResults^ section.
Statistical analysis
1. Measurement of Treatment Effect
Statistical analysis was conducted using Review Manager
(RevMan) version 5.3 (Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014). Only summary
estimates are reported (no individual patient meta-analysis).
For continuous outcomes, the mean and standard deviation
(SD) (such as duration of respiratory support) reported in each
study were collected and analysed and presented as mean
differences (MD) along with 95% confidence intervals (CIs).
Means and SDs were estimated from studies (total six studies)
reporting continuous outcomes as medians and interquartile
ranges by using methods described by Wan et al. [16]. For
categorical outcomes (such as survival or BPD), data was
extracted for each intervention group for analysis and present-
ed as risk ratio (RRs) with 95% CI. Estimation of number
needed to treat/harm, along with their 95% confidence inter-
vals, were undertaken for significant results using GraphPad
Prism QuickCalc (GraphPad software 2017, https://graphpad.
com/quickcalcs/), according to the methods of Newcombe/
Wilson with continuity correction [17]. All main results were
rated independently by the authors using the Grade system
(https://gdt.gradepro.org/app/handbook/handbook.html) and
presented in a summary-of-findings (SoF) table. A pre-
specified sub-group analysis was conducted by including
studies in which hydrocortisone was used for the prevention
of BPD (and not for the treatment of systemic hypotension).
Significance was set at p < 0.05.
2. Assessment of Bias in Included Studies
All studies included in final analysis were assessed for risk
of bias (low, high, or unknown) using a domain-based flow-
sheet (as used by the Cochrane Collaboration). For each do-
main, a judgement was made on likely magnitude and direc-
tion of the bias and its likely impact on the outcomes.
Disagreements were resolved by consensus. A judgement
was made on the overall risk of bias based on the above
domains.
3. Assessment of Heterogeneity
Heterogeneity was quantified using Inaccuracy2 (I2) statis-
tic and stratified as moderate (I2 < 50%) or substantial (I2 ≥
50%) (http://handbook.cochrane.org/). To calculate pooled
estimate of effect size, a fixed-effect model was used if mod-
erate heterogeneity was detected, and a random-effect model
was used if substantial heterogeneity was detected.
Ethical approval
No specific ethical approval was required for this meta-
analysis as all original studies had individual ethical approval.
The review was prospectively registered on PROSPERO with
an identification number of CRD42017073615 (http://www.
crd.york.ac.uk/PROSPERO/display_record.asp?ID=
CRD42017073615).
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Results
Search records, filtering and study flow diagram is presented
in Fig. 1. In total, 22 full-text articles and conference abstracts
were included in the qualitative analysis—18 for the early use
and 4 for the late use of hydrocortisone.
One full-text article and one conference paper for the early
use and one full-text paper for the late use of hydrocortisone
were excluded from final meta-analysis (details below), leav-
ing 16 papers for the early use and 3 for the late use in the
quantitative synthesis.
A summary of the risk of bias in the included studies as
agreed by the authors is presented in supplementary Fig. 1.
Although some of the domains in the included studies had
unclear or high risk of bias, all the studies had an overall
low risk of bias.
A total of 13 studies investigated the use of early hydrocor-
tisone in preterm infants in the first week of life of which 12
were published as full-text articles [18–29]. One study was
only published as an abstract [30] and used both hydrocorti-
sone and caffeine in the experimental group, with placebo in
the control group. As caffeine is known to have a significant
effect on BPD, it was not possible to separate the effects of
these two drugs from each other in the results from this study,
and this abstract was excluded from further analysis. Of the 12
other studies which were included in the quantitative analysis,
four published follow-up studies which were included in the
long-term analysis [31–35]. One of the follow-up studies re-
ported outcomes at pre-school age and was not included in the
meta-analysis as this was the only study to do so [34]. Details
of all included studies are presented in Table 1 and supple-
mentary Table 2. Both the pooled mean GA (MD 0.05 weeks,
Fig. 1 Study flow diagram,
showing filtering of papers at
each stage
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95% CI [− 0.09, 0.18], p = 0.49) and mean birth weight (−
3.92 g, [− 21.08, 13.24], p = 0.65) of the full cohort were
comparable between the two groups of infants from the in-
cluded studies.
Summary of findings after early use of hydrocortisone
is presented in Table 2. A total of 10 studies reported the
primary outcome. Pooled estimate including data from all
of the studies (1378 infants) showed a significantly higher
risk of survival without BPD for the group of infants
receiving hydrocortisone in the first week of life (RR
1.13 [1.01, 1.26], p = 0.04, Fig. 2a), compared to placebo
(or other active control). From our estimate, 18 preterm
infants would need to be treated (NNT) with early hydro-
cortisone for one infant to survive without BPD (95% CI
9.2, 314.2). A funnel plot for this outcome did not suggest
a significant publication bias (supplementary Fig. 2a). As
evident from Table 1, not all studies intended to look at
the outcome of BPD; some studies used hydrocortisone to
treat systemic hypotension in the first week of life [19, 21,
23–25]. We undertook a sub-group analysis of five studies
(1019 infants) using early systemic hydrocortisone for the
prevention of BPD as their primary outcome [20, 22,
27–29], and pooled data also showed a significantly
higher risk of survival without BPD for infants in the
hydrocortisone group (1.19 [1.04, 1.35], p < 0.01, Fig.
2b). Thirteen infants would have to be treated with early
systemic hydrocortisone for one infant to survive without
BPD (95% CI 7.1, 56.1).
When all studies were included, the incidence of BPD
in survivors at 36 weeks (0.91 [0.81, 1.03], p = 0.15,
Fig. 3a) and total survival to 36 weeks (1.03 [0.98,
1.08], p = 0.19) were not significantly different between
the groups. However, in the sub-group analysis of the
BPD studies, the risk of BPD in survivors at 36 weeks
was significantly lower (0.84 [0.72, 0.98], p = 0.03, NNT
14 [7.2, 164.6], Fig. 3b), although survival to 36 weeks
was comparable between the groups (1.04 [0.98, 1.10]
p = 0.20). Total survival to discharge was higher in the
hydrocortisone group (1.05 [1.00, 1.11], p = 0.04, NNT
24 [12.1, 524.2]) when all studies were included but
failed to reach statistical significance in the sub-group
analysis (1.06 [1.00, 1.13], p = 0.06). Gastrointestinal per-
foration, which was significantly higher in the group of
infants receiving hydrocortisone (all studies: 1.69 [1.07,
2.68], p = 0.03, number needed to harm (NNH) 30 [15.9,
193.9], Fig. 4a; BPD-studies: 1.76 [1.09, 2.84], p = 0.02,
NNH 28 [15.0, 159.2], Fig. 4b),
All short-term safety and other outcomes during the first
admission of the infants from birth to discharge (or death) are
summarised in Table 3 along with the sub-group analysis.
Early treatment with hydrocortisone significantly reduced
the risk of treatment for PDA (all-studies: 0.66 [0.52, 0.84],
p < 0.01, NNT 11 [6.8, 25.9], supplementary Fig. 3a; BPD-Ta
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studies: 0.66 [0.49, 0.88], p < 0.01, NNT 11 [6.3, 37.6], sup-
plementary Fig. 3b).
Only a minority of the original studies reported any
long-term outcomes (5 out of 11). The main results are
summarised in Table 4. Infants who received early hydro-
cortisone had a significantly higher risk of survival with-
out moderate-severe NDI (all studies: 1.13 [1.02, 1.26],
p = 0.02, supplementary Fig. 4a; BPD-studies: 1.14 [1.03,
1.27], p = 0.02, supplementary Fig. 4b), compared to in-
fants in the control group. For every 14 infants treated
with early hydrocortisone after birth, one infant is estimat-
ed to survive without moderate-severe NDI (NNT, 95%
CI 7.4, 129.4). If only the BPD studies were considered,
the NNT was 13 (95% CI 7.0, 81.1).
Three studies randomised infants to receive hydrocortisone
after the first week of life [36–38], with one follow-up study
[39]. The study by Kazzi et al. treated preterm infants with
systemic dexamethasone in the first week of life (7 days),
followed by systemic hydrocortisone in tapering doses for
the next 10 days. As early dexamethasone is known to have
a significant effect on BPD [6], it was not possible to separate
its effect from those of hydrocortisone. Thus, this trial was
excluded from further analysis. Summary of results from the
remaining two trials are presented in Table 5. Although both
of these studies used hydrocortisone in ventilator-dependent
preterm infants beyond the first week of life for the prevention
of BPD, there were several differences between their design
and conduct. Parikh and colleagues [37] randomised infants
with a birth weight ≤ 1000 g between 10 and 21 days of life to
a cumulative dose of 17 mg/kg of hydrocortisone over 7 days
or placebo, while Onland and colleagues [38] randomised
infants born at < 30 weeks (or < 1250 g birth weight) between
7 and 14 days of life to a cumulative dose of 72.5 mg/kg of
hydrocortisone over 22 days or placebo. Results reported by
the two trials were not always comparable, and only some of
the outcomes could be pooled together in the meta-analysis
presented in Table 5. Apart from a significantly higher risk of
needing treatment for hyperglycaemia in infants receiving hy-
drocortisone (2.31 [1.30, 4.11], p < 0.01), all other outcomes
were comparable between the groups. There was a trend to-
wards more infants in the hydrocortisone group surviving to
discharge (1.12 [0.99, 1.26], p = 0.07). Due to the paucity of
studies, no recommendations can be made for the use of late
hydrocortisone for the prevention of BPD in preterm infants.
Discussion
Preterm infants receiving early systemic hydrocortisone
had a significantly higher chance of survival without
BPD (composite outcome) at 36 weeks PMA, compared
to control infants (NNT = 18). This effect was also evident
a
b
Fig. 2 Forest-plot of pooled effect estimate for survival without BPD at 36 weeks corrected gestational age with early systemic hydrocortisone for a all
studies and b studies with BPD as primary outcome
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ab
Fig. 4 Forest plots of pooled effect estimates for gastrointestinal perforation with early systemic hydrocortisone for a all studies and b studies with BPD
as primary outcome
a
b
Fig. 3 Forest plots of effect pooled estimates for BPD at 36 weeks corrected gestational age in survivors with early systemic hydrocortisone for a all
studies and b studies with BPD as primary outcome
Eur J Pediatr
in a sub-group of trials where BPD was the intended pri-
mary outcome with NNT of 13. Risk of gastrointestinal
perforation was significantly higher in infants receiving
hydrocortisone. At follow-up (up to 2 years of age), in-
fants receiving early systemic hydrocortisone had a sig-
nificantly higher chance of survival without moderate-to-
severe NDI (composite outcome) compared to control in-
fants (NNT 14).
Our review on hydrocortisone has been updated since the
Cochrane review published in 2017, with several differences.
We identified two extra eligible studies, which have been in-
cluded in the meta-analysis. We have conducted a sub-group
Table 3 Summary of short-term safety and other outcomes during stay for use of early hydrocortisone
Outcome Hydrocortisone Control Number of trials Risk ratio (95% CI)
OR SMD (95% CI)
p value NNT/H (95% CI)
Events Total Events Total
All studies
Survival to discharge 602 728 583 743 12 1.05 (1.00, 1.11) 0.04 24 (12.1, 524.2)
Sepsisa 253 702 236 714 10 1.09 (0.95, 1.25) 0.22
Pulmonary air leak 48 609 43 623 5 1.13 (0.77, 1.67) 0.54
Pulmonary haemorrhage 53 584 41 598 4 1.32 (0.89, 1.95) 0.16
GI bleeding 2 25 1 26 1 2.08 (0.20, 21.52) 0.54
Treated for hyperglycaemia 207 508 192 520 6 1.10 (0.95, 1.28) 0.20
Treated for hypertension 4 196 5 198 2 0.80 (0.22, 2.93) 0.74
Any IVH 93 217 82 222 3 1.16 (0.92, 1.46) 0.20
IVH grade III–IVb 102 687 108 704 10 0.97 (0.76, 1.25) 0.83
PVL 21 584 30 607 8 0.75 (0.44, 1.27) 0.28
NEC 54 705 55 719 11 1.00 (0.70, 1.43) 0.99
Discharged with home oxygen (survivors) 33 348 43 341 4 0.76 (0.50, 1.15) 0.20
Duration of mechanical ventilation (days) 425 430 8 −0.63 (−3.02, 1.77) 0.61
Duration of stay (days)c 385 388 7 −1.94 (−6.76, 2.89) 0.43
Treated for PDAd 79 439 125 458 5 0.66 (0.52, 0.84) < 0.01 11 (6.8, 25.9)
Treated for ROP 25 477 30 486 5 0.83 (0.50, 1.37) 0.46
BPD studies
Survival to discharge 417 505 401 515 5 1.06 (1.00, 1.13) 0.06
Sepsis 179 505 155 514 5 1.17 (0.99, 1.40) 0.07
Pulmonary air leak 30 460 29 471 3 1.04 (0.64, 1.70) 0.86
Pulmonary haemorrhage 37 435 30 446 2 1.26 (0.79, 2.01) 0.33
GI bleeding 2 25 1 26 1 2.08 (0.20, 21.52) 0.54
Treated for hyperglycaemia 196 460 184 472 3 1.09 (0.94, 1.28) 0.25
Treated for hypertension 4 180 5 180 1 0.80 (0.22, 2.93) 0.74
Any IVH 93 217 82 222 3 1.16 (0.92, 1.46) 0.20
IVH grade III–IV 77 497 74 509 5 1.07 (0.80, 1.44) 0.65
PVL 16 415 23 431 4 0.72 (0.39, 1.34) 0.30
NEC 29 504 31 513 5 0.95 (0.58, 1.55) 0..84
Discharged with home oxygen (survivors) 18 246 24 238 3 0.74 (0.42, 1.28) 0.28
Duration of mechanical ventilation (days) 249 249 4 − 2.69 (− 6.98, 1.59) 0.22
Duration of stay (days) 222 221 4 − 1.02 (− 6.35, 4.31) 0.71
Treated for PDAd 54 300 85 312 3 0.66 (0.49, 0.88) < 0.01 11 (6, 3, 37.6)
Treated for ROP 24 453 28 462 4 0.85 (0.51, 1.42) 0.54
a Only first episode of sepsis included from Biswas 2003
b Bourchier (1997) and Efird (2005) reported IVH grades II–IV
c Efird (2005) reported duration of stay in survivors only
d Baud (2016) and Biswas (2003) reported numbers of infants who had surgery for PDA
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analysis with all studies where BPD was the primary outcome.
In addition, we have looked at more clinically relevant out-
comes which would help clinicians to take decisions on the
ward, including proportions of infants in each group who actu-
ally received treatment for hyperglycaemia, hypertension, PDA
and ROP. The diagnosis and the exact clinical significance of
these morbidities are controversial; treatment for these
morbidities indicate crossing of a pragmatic threshold, which
is of real clinical interest (rather than just the diagnosis). Thus,
we believe these clinically useful outcomes are more relevant
for clinicians. We have used only published data for our anal-
ysis, which can be easily accessed and verified by all readers.
Our review includes all published trials of postnatal hydro-
cortisone (14 trials in total), including 1633 preterm infants.
Table 4 Summary of long-term safety outcomes of early hydrocortisone
Outcome Hydrocortisone Control Number of trials Risk ratio (95% CI) p value NNT
(95% CI)
Events Total Events Total
All studies
Death until last FU 91 482 112 494 4 0.83 (0.65, 1.06) 0.14
Survival without moderate-severe NDI 281 443 256 455 4 1.13 (1.02, 1.26) 0.02 14 (7.4, 129.4)
Any NDI at FU 41 138 45 138 2 0.91 (0.64, 1.29) 0.60
Severe NDI at FU 19 217 26 207 2 0.70 (0.40, 1.22) 0.20
Cerebral palsy (survivors and FU) 34 374 31 359 5 1.06 (0.67, 1.67) 0.81
BPD studies
Death until last FU 83 460 103 472 3 0.83 (0.64, 1.07) 0.15
Survival without moderate-severe NDI 271 422 245 434 3 1.14 (1.03, 1.27) 0.02 13 (7.0, 81.1)
Any NDI at FU 39 126 44 126 1 0.89 (0.62, 1.26) 0.50
Severe NDI at FU 19 217 26 207 2 0.70 (0.40, 1.22) 0.20
Cerebral palsy (survivors and FU) 32 362 30 347 4 1.03 (0.64, 1.64) 0.91
Results from Bonsante 2007 were reported in the paper by Peltoniemi 2009, Fitzhardinge reported severe NDI at 1-year of age, and Watterberg 2007
reported severe NDI)
FU follow-up
Table 5 Summary of outcomes of late hydrocortisone. (FU follow-up)
Outcome Hydrocortisone Control Number of trials Risk ratio (95% CI)
SMD (95% CI)
p value
Events Total Events Total
Survival without BPD at 36 weeks postmenstrual age 81 212 77 222 2 1.10 (0.88, 1.37) 0.41
BPD at 36 weeks in survivors 120 176 115 170 2 1.01 (0.88, 1.17) 0.87
Survival to 36 weeks postmenstrual age 176 212 170 223 2 1.09 (0.99, 1.20) 0.08
Survival to discharge 153 212 144 223 2 1.12 (0.99, 1.26) 0.07
Sepsis 104 212 126 223 2 0.87 (0.73, 1.04) 0.12
GI perforation 6 212 9 223 2 1.05 (0.11, 10.25) 0.96
Hypertension 27 212 26 223 2 1.10 (0.70, 1.73) 0.68
Treated for hyperglycaemia 33 181 15 190 1 2.31 (1.30, 4.11) < 0.01
Treated for PDA 72 181 78 190 1 0.97 (0.76, 1.24) 0.80
IVH grade III–IV 2 181 3 190 1 0.70 (0.12, 4.14) 0.69
PVL 7 181 9 190 1 0.82 (0.31, 2.15) 0.68
NEC 19 212 22 223 2 0.91 (0.51, 1.63) 0.75
ROP >Grade II 44 181 42 190 1 1.10 (0.76, 1.59) 0.62
Duration of respiratory support 212 223 2 1.68 (−3.31, 6.67) 0.51
Death until last FU 9 29 12 29 1 0.75 (0.37, 1.50) 0.42
Survival without NDI (any) 9 28 7 29 1 1.33 (0.57, 3.09) 0.50
Cerebral palsy (survivors and FU) 3 20 1 17 1 2.55 [0.29, 22.31] 0.40
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There is a modest but statistically significant increase in the
chance of survival without BPD after receiving early postnatal
hydrocortisone with an estimated NNTof 18 infants, although
the imprecision of this estimate is acknowledged in the wide
confidence interval. The sub-group analysis confirmed this
effect with a smaller NNT of 13. Importantly, the follow-up
studies, which included a total of 898 infants from 4 studies,
demonstrated a significant increase in survival without
moderate-to-severe NDI, with an NNT of 14. The incidence
of cerebral palsy in survivors and NDI at follow-up was com-
parable between the two groups of infants. Though many of
the studies did not report follow-up, the favourable
neurodevelopmental results would be reassuring for clinicians
that the long-term effects of early postnatal hydrocortisone use
are in sharp contrast to those of early dexamethasone use in
preterm infants [6]. However, we have only been able to an-
alyse neurodevelopmental outcomes up to 2 years of age. One
small study, involving 51 preterm infants, with longer-term
follow up, have reported increasing trends towards NDI in
infants receiving hydrocortisone at 5–7 years of age [34], sug-
gesting collection of longer-term data would be prudent.
Significantly more infants who received hydrocortisone sur-
vived to discharge (p = 0.04), although this outcome failed to
reach statistical significance in the sub-group analysis (p =
0.06).
While the above outcomes are encouraging, use of early
hydrocortisone resulted in a significantly higher risk of GI
perforation, with an NNH of 30 infants. While hydrocorti-
sone itself could cause intestinal perforation, an interaction
between the steroid and indomethacin (or ibuprofen) has
been strongly implicated as a significant contributor for
this effect. Trials reporting increased incidence of GI per-
foration all used hydrocortisone with concurrent medical
treatment for PDA [22, 26, 27, 29]. A similar interaction
between early systemic dexamethasone and indomethacin
were also noted in earlier studies [40]. Bourchier et al. [23]
did not report an increased incidence of GI perforation,
although this trial used the highest cumulative dose of ear-
ly hydrocortisone but not in combination with PDA treat-
ment. Use of ibuprofen for PDA was excluded from the
PREMILOC trial in the first 24 h of life to avoid sponta-
neous GI perforations [20]. While these results generate
serious concern, current clinical practice for managing
PDAs are changing to a more conservative approach [41],
since the spontaneous closure rate of PDAs remain high
and early prophylactic treatment has failed to demonstrate
significant clinical benefits. In addition, use of antenatal
and postnatal steroids possibly decreases the incidence of
PDA due to the inhibition of arachidonic acid and its me-
tabolites, which have a significant effect on the patency of
the duct [42].
The regime of early hydrocortisone was variable among the
trials, but there were two broad groups: two trials used a total
dose of ≥ 30 mg/kg but did not report any respiratory out-
comes [18] or were primarily aimed for blood pressure man-
agement [23]; the rest used cumulative doses of ≤ 15 mg/kg
including the five trials which used hydrocortisone for treat-
ment of BPD. The chronic replacement dose of hydrocorti-
sone in newborn infants, as recommended in the British
National Formulary for Children (https://bnfc.nice.org.uk/
drug/hydrocortisone.html), is 8–10 mg/m2/day, which is
approximately equal to 1 mg/kg/day. The only appropriately
powered trial, which had respiratory end-points as its primary
outcome used this dose of hydrocortisone (cumulative dose 8.
5 mg/kg over 10 days) and demonstrated significant clinical
benefits [20]. While the most appropriate dose of hydrocorti-
sone cannot conclusively be recommended from these results,
the dose regime used by the PREMILOC trial seems to be safe
and effective for survival without BPD in preterm infants.
Four trials undertook formal adrenal stimulation tests after
the course of hydrocortisone and reported no significant dif-
ference in cortisol levels, thus allaying fears of cortical sup-
pression [20, 23, 27, 43].
Our review has several strengths. We have conducted a
thorough electronic and manual search and believe that we
have identified all published trials of hydrocortisone use in
preterm infants, including two studies which are not included
in the Cochrane review. Three authors have independently been
involved in short listing and data collection, with joint cross-
checking of all data and results. We have excluded trials where
the individual effect of hydrocortisone could not be ascertained
due to the use of concurrent drugs with known effects on BPD.
Our analysis follows standard methods as recommended by the
Cochrane collaboration (http://handbook-5-1.cochrane.org/).
We have also looked at clinically relevant outcomes.
Although many of the trials were not intended for the
prevention of BPD but reported this outcome, we undertook a
sub-group analysis by excluding these trials to reach robust
conclusions. However, there are several limitations which are
mostly related to the original studies. A number of trials in our
analysis have included small numbers of infants increasing the
chance of a type-I error [44], although they have all received
lower weightage in the analyses. The increase in the incidence
of gastrointestinal perforation with early systemic hydrocorti-
sone remains of concern for clinicians, although this was asso-
ciated mostly with concurrent treatment for PDA. However,
this significant difference did not seem to have an overall effect
in any other outcomes, including survival. In addition, early
hydrocortisone seems to have a treatment-sparing effect on
PDAs, which may mitigate some of this concern. While the
long-term outcomes are reassuring, we acknowledge the reduc-
tion in confidence in this outcome due to incomplete follow-up
in studies. The Premiloc study [20] used the Brunet-Lezine test
to assess neurodevelopment at follow-up, while most of the
other studies used variations of the Bailey’s test for this assess-
ment. One study from Brazil, comparing these two assessment
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methods, reported moderate correlation between them in most
domains but strong correlation in the language domain [45].
However, this limits our ability to interpret the results from the
long-term outcomes.
Conclusions
Early systemic hydrocortisone in preterm infants is effective
in increasing the chances of survival without BPD at 36 weeks
postmenstrual age. Incomplete long-term follow-up suggests
significantly increased chance of survival without moderate-
to-severe NDI up to 2 years of age, although the methods used
to assess this outcome were inconsistent. An increased risk of
GI perforation, mostly in conjunction with early treatment for
PDA, remains of concern. Future trials should focus on ascer-
taining the most appropriate dose of early hydrocortisone in
preterm infants for the prevention of BPD and undertake a
longer period of follow-up to conclusively establish safety.
In addition, recent trials of alternative delivery methods of
early steroids have also shown encouraging results and should
be further studied so that the optimum strategy to reduce BPD
can be identified in these vulnerable infants.
Use of systemic hydrocortisone beyond the first week of
life, especially in infants who become ventilator depen-
dent, needs further research. Currently, one ongoing trial
is recruiting infants in the second week of life to receive
systemic hydrocortisone (https://clinicaltrials.gov/ct2/
show/NCT01353313). Results from trials using late
dexamethasone (https://www.npeu.ox.ac.uk/minidex) may
also increase our knowledge in this area.
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